| RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA |
Rejected |
- |
4 |
A8081046 |
N/A |
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis
|
Rejected |
|
|
ONC-MA1001
|
N/A |
| An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS) |
Completed |
Fingolimod |
4 |
CFTY720D-MAX-TH-01 |
King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah) |
| "(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated " |
Completed |
Ranibizumab 10mg/ml (Lucentis) |
4 |
RFB002A2406 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh) |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care |
Ongoing |
KB195 |
2 |
K020-218 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE). |
Completed |
Zoledronic acid |
4 |
CZOL446H-MAX-SA-01 |
King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh) |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS |
Terminated |
Ocrelizumab |
3b |
MN39159 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. |
Terminated |
RO7034067 |
2 |
BP39056 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS |
Ongoing |
Emicizumab |
3 |
MO39129 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. |
Completed |
DICLOFENAC POTASSIUM |
BE |
42856 |
Saudi Ajal |
